We have generated a transgenic mouse model for astrocytoma by expressing the v-src kinase under control of the glial ®brillary acidic protein (GFAP) gene regulatory elements in astrocytes. Abnormal astrogliosis was observed in all transgenic animals already at 2 weeks postnatally, frequently followed by the development of dysplastic changes. Later, small proliferative foci arose, and overt astrocytoma developed in the brain and spinal cord in 14.4% of mice after a follow up time of 65 weeks. While early lesions were histologically consistent with low-grade astrocytoma, at later stages most tumors were highly mitotic and frankly malignant. Vascular endothelial growth factor (VEGF) was expressed by tumor cells already at early stages, suggesting induction by v-src, and it was most pronounced in pseudopalisading cells surrounding necrotic areas, implying additional upregulation by hypoxia. In larger lesions, mitotic activity and expression of¯k-1, the cognate receptor of VEGF were induced in endothelial cells. Therefore, end-stage tumors mimicked the morphological and molecular characteristics of human glioblastoma multiforme. Time course and stochastic nature of the process indicate that v-src did not suce for malignant transformation, and that astrocytomas were the result of a multistep process necessitating co-operation of additional genetic events.
Introduction
Astrocytomas are the most common glial tumors, which account for nearly 50% of human brain tumors. They are classi®ed into grade I-IV according to WHO criteria (Kleihues et al., 1993) . Malignant WHO grade III and WHO grade IV astrocytoma (anaplastic astrocytoma and glioblastoma multiforme, respectively) are among the most aggressive human tumors, and glioblastomas have a median survival of 6 ± 12 months after the onset of clinical symptoms. Surgical, radio-and chemotherapeutic treatments are only moderately successful in prolonging the life expectancy since total tumor ablation is rarely attained and recurrence is almost inevitable. Even low-grade`benign' astrocytomas tend to give rise to local re-growths which display a progressively malignant phenotype. The latter phenomenon represents a therapeutic problem, and is one of the main determinants of the dismal long-term prognosis.
In contrast to the malignant progression in colon and skin carcinogenesis, for which many molecular details are well understood (Vogelstein and Kinzler, 1993) , the genetic basis of astrocytoma progression is largely unknown. Some authors hypothesize that malignant astrocytomas arise via distinct genetic pathways (Louis and Gusella, 1995; von Deimling et al., 1995) . However, the molecular substrates of many cytogenetically detectable alterations have not yet been elucidated (Jen et al., 1994; von Deimling et al., 1994) . Consequently, the mechanisms by which the tumor is driven from an asymptomatic into a clinically overt stage, and then progresses from a benign,`low-grade' lesion to a malignant`high-grade' astrocytoma and eventually to glioblastoma multiforme, are poorly understood.
It is well known that src activation is able to induce neuroectodermal tumors in rodents (Aguzzi et al., 1991) and that experimental gliomas can be induced by intracerebral inoculation of RSV in dogs (Haguenau, 1981) . In an immunohistochemical study including 108 human brain tumors several astrocytomas were found to express the src gene product, while other brain tumors and normal brain tissue were negative (Takenaka et al., 1995) .
We reasoned that cell-directed expression of v-src might represent a suitable ®rst hit to induce astrocytomas in transgenic mice. The choice of v-src as a transgene was also based on the ®nding that ampli®cation of the EGF-R and PDGF-R genes is frequently found in glioblastoma (Ohgaki et al., 1995) , and that tyrosine kinases of the Src family have been shown to bind directly to activated EGF receptor (Luttrell et al., 1994; Sato et al., 1995) .
Src (pp60 c-src ) is an intracellular tyrosine kinase expressed ubiquitously in mammalian cells, with highest levels encountered in brain and platelets (Brugge et al., 1987) . v-src, the transforming gene of the Rous Sarcoma Virus (RSV) (Levinson et al., 1978) encodes pp60
v-src which is nearly identical to pp60 c-src , but lacks the carboxy-terminal region comprising Tyr-527 which switches o its kinase upon phosphorylation and is therefore constitutively active as a tyrosine kinase (Cooper et al., 1986) . An in vivo model for astrocytoma induction would be desirable in order to elucidate the molecular details of its oncogenesis. Earlier studies have employed chemical mutagenesis to induce tumors resembling gliomas in rats (Bilzer et al., 1989; Burger et al., 1988; Kleihues et al., 1989) . These systems yielded highly malignant tumors, but failed to reproduce the biological behavior of low grade astrocytomas and did not prove very useful for the identi®cation of genes involved in tumor progression. No transgenic model for astrocytoma is currently available.
In an attempt to model astrocytoma progression, we have expressed the v-src oncogene in astrocytes of transgenic mice. To target expression of the transgene to astrocytes, we have cloned v-src into a construct harboring the entire genomic structure of the mouse glial ®brillary acidic protein (GFAP) gene (Mucke et al., 1991; Toggas et al., 1994) (Figure 1a ). Mice expressing this construct developed astrocytic tumors corresponding to human low-and high-grade astrocytomas. Although dysplastic and preneoplastic lesions occurred in most transgenic mice, the penetrance of bona ®de astrocytomas was low (520%), indicating that neoplastic transformation is a stochastic event driven by additional genetic hits. Therefore, these transgenic mice may represent a useful tool for dissecting the multiple genetic steps involved in malignant progression of astrocytomas.
Results

Generation of GFAP-v-src transgenic mice
We have produced three lines of transgenic mice harboring the coding sequence of the viral Src kinase of Rous sarcoma virus (RSV) under control of the regulatory elements of the glial ®brillary acidic protein (GFAP) gene. Expression of the transgene was targeted to astrocytes by inserting v-src into exon 1 of a modi®ed 17 kb expression construct (Figure 1a ) consisting of the entire exon/intron structure of the mouse GFAP gene and the 5' regulatory sequences with the basal promoter plus an additionally introduced SV40 (simian virus 40) late gene splice and polyadenylation signal in exon 1 (Toggas et al., 1994) . Three independent founder animals were obtained which passed the transgene onto their progeny hemizygously in a Mendelian fashion. Southern hybridization analysis revealed that two of the three lines (here referred to as src1 and src2) carried the fulllength insert, while the third line (src3) showed a truncation in the 3' region of the v-src gene ( Figure  1b ). Copy numbers (src1, 5; src2, 32, src3, 8) were estimated by normalizing transgenic to endogenous GFAP signals.
Analysis of transgene expression
Transgene expression was investigated by RT ± PCR, Northern blotting and in situ hybridization. Spliced transcripts encoding v-src were found in whole brain RNA from transgenic mice but not from control littermates (Figure 1c Southern hybridization analysis of genomic DNA from mice of F 2 generation of three dierent v-src transgenic lines. 10 mg tail DNA each were digested with the indicated restriction enzymes, separated on an agarose gel and transferred to a nylon membrane. For the detection of endogenous and transgenic GFAP blots were hybridized with a 32 P-labeled S®I-fragment of the transgene construct. In the PvuII digest (left panel), the two slowest migrating bands are indicative of a dierent integration locus in line src2. Digestion with BamHI revealed a truncated vsrc gene in line src3 (right panel). The bands common to all lanes represent endogenous GFAP signals. By normalizing transgenic to endogenous signals line src1 was estimated to have ca. 5 copies, line src2 ca. 32 copies, and line src3 ca. 8 copies of the transgene.
M, molecular weight standard; src1, src2 and src3, independent transgenic mouse lines; wt, wild-type (c) RT ± PCR analysis of transgene expression, yielding 412 bp PCR products (arrowhead) for the spliced GFAP v-src trancript, in comparison to endogenous GFAP (585 bp) and b-actin (549 bp) mRNA PCR, transgene transcripts were also detectable in lung, thymus, spleen and gonads (Figure 1c) . Northern blot analysis with poly(A) + mRNA revealed transgene expression in the brain and a weak signal in testes of transgenic mice (data not shown). In addition, weak expression of the endogenous GFAP gene was found in testes as described previously (Holash et al., 1993) .
The cellular distribution pattern of transgene expression was assessed by in situ hybridization. v-src expressing cells were found in the brain at sites of endogenous GFAP expression, i.e. most conspicuously in the brain stem, dorsal thalamus, cerebellum ( Figure  2 ) and to a lesser extent in the subcortical white matter in the spinal cord. Combined sequential immunocytochemistry and in situ hybridization for GFAP protein and v-src mRNA identi®ed these cells as astrocytes (data not shown). No transgenic v-src or endogenous GFAP message was detectable in other tissues by this method. In situ hybridization for v-src, GFAP and synaptophysin mRNA on adjacent sections con®rmed the localization of transgene expression to astrocytes (Figure 2 ). Two weeks postnatally, only low levels of vsrc RNA were detectable in some of the reactive astrocytes. However, as early as 4 weeks postnatally, many astrocytes, especially those with dysplastic changes, expressed high levels of v-src RNA ( Figure  4e ). Upregulation of v-src RNA expression was markedly enhanced in proliferating preneoplastic lesions, and in overt tumors v-src was amply expressed in all tumor cells. In addition, low levels of both GFAP and v-src RNA were detected in Schwann cells of peripheral nerves.
Pathological phenotype of GFAP-v-src transgenic mice
At birth, transgenic mice were indistinguishable from their littermates. However, already at 2 weeks of age some of them appeared retarded in growth, and a few had hydrocephalus. At later stages, cerebellar ataxia was the most prominent clinical ®nding in those mice which were found to be aected by tumors. Altogether, only a small fraction of mice developed clinical symptoms (Figure 3 ), while the majority lived for up (Table 1) .
Upon histological analysis, pathological astrogliosis ( Figure 4a ) was observed in all mice carrying the fulllength insert (src1 and src2) as early as 2 weeks after birth. GFAP-immunoreactive cells had pale, eccentric nuclei and hypertrophied processes characteristic of reactive astrocytes. These relatively mild signs were followed by the development of dysplastic changes in astrocytes in most cases: frequent occurrence of bizarre vacuolated cells (Figure 4b ) and binucleated cells (Figure 4c ). These lesions were characterized by low proliferative activity. In addition, atypical gemistocytelike astrocytes with retracted processes and a particularly strong GFAP-staining were observed (Figure 4d, e) . These cells gave rise to preneoplastic foci with enhanced proliferative activity.
In 10 ± 20% of animals, overt tumors developed: some tumors were multifocal with features of anaplastic astrocytoma (Figure 5a ± e). Other tumors histologically resembled gemistocytic astrocytoma (Figure 5f, g ). Almost all the observed astrocytomas arose in the brainstem or thalamus, corresponding to the regions with astrogliosis and preneoplasia. One mouse which developed paraplegia had a large tumor that compressed the spinal cord from the lumbar to the cervical segments. All tumors exhibited strong expression of GFAP and a high proliferation index (Figure 5e ). An identical progression of pathologic changes from astrogliosis to anaplastic astrocytoma was observed in mice of both lines. The stages of tumor development are summarized in Table 1 .
In addition, three mice of line src2 developed tumors with features suggestive of schwannoma. One mouse developed a subcutaneous tumor composed of spindle shaped cells which formed bundles and whorls. This tumor also contained areas of necrosis and pathological vessels indicative of tumor angioneogenesis (Figure 6a ± e). Another animal developed a large tumor at the skull base, which originated from the trigeminal nerve and displayed the classical histopathological appearance of schwannoma with nuclear palisades and focal regressive changes analogous to Antoni A and B pattern (Kleihues et al., 1993) . A third mouse developed paraplegia due to an extramedullary spinal tumor probably originating from a spinal nerve root, with similar appearance. All three tumors displayed moderate GFAP immunoreactivity and stained positive for reticulin. Angiogenesis has been proposed to be the rate-limiting factor for solid tumor growth (Folkman, 1995; Hanahan and Folkman, 1996) . In situ hybridization analysis revealed expression of VEGF in single astrocytes in the brains of transgenic mice already at early stages (Figure 6f ). This in vivo result extends earlier observations showing transactivation of the VEGF promoter by v-Src in U87 and 293 cells (Mukhopadhyay et al., 1995a) in vitro. However, in preneoplastic lesions and tumors, expression of VEGF was widespread and most prominent in pseudopalisading cells surrounding necrotic areas, suggesting additional upregulation by hypoxia (Figure 6c ). In larger lesions, endothelial cells displayed induction of k-1, the cognate receptor of VEGF ( Figure 6d ) and mitotic activity (Figure 6e ). In contrast, there was only weak induction of¯t-1 (data not shown).
Establishment of tumor cell line
In order to study GFAP-v-src transgenic tumor cells in vitro, we have derived cells from a subcutaneous tumor of a src2 animal after dissociation through cell strainers. The tumor cells were grown for over 20 passages in normal cell culture medium (DMEM) without any change in growth kinetics. In vivo growth characteristics of the cell line, designated TU2449, were enhanced attachment (20 min) after plating, a high growth rate (population doubling 1d) and an elongated morphology (Figure 7a) .
Transgene expression was investigated by Northern and Western blot analysis. High expression of v-src mRNA was detected speci®cally in TU2449 cells (Figure 7c , left). GFAP protein expression was stronger, and the total amount of Src proteins was higher than those detected in the rat glioblastoma cell line C6 using antibodies to GFAP and pp60 src ( Figure  7c, right) .
Tumorigenicity of TU2449 cells in vivo was assessed by injection of 1610 6 and 1610 5 cells/site into thē ank and into the neck of 8 week-old nude mice (ICR nu/nu ). In all animals injections resulted in the formation of solid GFAP-positive tumors of 51 cm in diameter within 7 and 14 days (Figure 7b ), respectively. The transplanted tumors maintained the morphological features of the parental tumor.
Discussion
We have generated transgenic mice which express a constitutively active Src kinase in astrocytes. Two independent transgenic mouse lines progressively developed astrogliosis, dysplastic and preneoplastic lesions, and eventually astrocytomas at 4 to 20 weeks of age. The third strain showed no pathological phenotype. In one out of seven analysed animals, mild astrogliosis was noted. This probably represents a nonspeci®c ®nding, since some degree of astrogliosis is also commonly found in aged wild-type mice.
The expression pattern of the transgene mirrored the normal GFAP expression in analogy to previous studies (Mucke et al., 1991; Toggas et al., 1994) . Since all GFAP-v-src transgenic mice carrying a fulllength v-src insert developed a pathological astrogliosis, which colocalized with the expression of the transgene, it appears that v-src expression in astrocytes induces GFAP transcription, and thereby enhances its own expression in an autocatalytic fashion. Further upregulation of v-src was found in proliferating preneoplastic lesions, and sustained levels of expression were observed in all tumors, indicating an essential function of v-src signaling in the induction and maintenance of the neoplastic phenotype. Although v-src transcripts were detected by RT ± PCR in other organs than the brain (Figure 1) , neither pathological changes nor tumor formation could be found in these organs. Yet it is noteworthy that three tumors with the morphology of schwannoma were found in line src2. This ®nding could be partly src (right). GFAP protein is strongly expressed in TU2449 cells, but only moderately in C6 cells. In TU2449 a cumulative Src signal is detected due to transgene expression explained by higher copy numbers in src2 (Figure 1b) , when compared to src1, yielding higher expression levels of v-src, or it might be the consequence of a dierent integration locus (Figure 1b , left panel) biasing site-speci®c expression level of the transgene in this line. Since low levels of GFAP are also present in Schwann cells of the peripheral nervous system (Galea et al., 1995) , and many schwannomas also express GFAP (Kawahara et al., 1988) it is conceivable that expression of v-src under the authentic transcriptional control of the GFAP regulatory elements was responsible for the transformation of these cells. This is supported by our ®nding of low levels of both GFAP and v-src RNA also in Schwann cells of peripheral nerves, which were probably the source of the signals detected in extracerebral tissues by RT ± PCR (JPS, JW and AA, unpublished data).
The transforming activity of the viral Src oncoprotein (Collett and Erikson, 1978) is dependent on its kinase activity and hence on its ability to phosphorylate speci®c cellular proteins at tyrosine residues (Hunter and Sefton, 1980) . The absence of a pathological phenotype in line src3 can be explained by the observation of a truncated v-src. It is predictable that this correlates with impaired Src activity.
Previous eorts to establish experimental animal models of astrocytomas have explored other species (rats, dogs) or have focused primarily on the eects of carcinogens on the rodent brain (Bilzer et al., 1989) . However, these protocols induced highly malignant and fast growing tumors, which were poorly suited for tumor progression studies. Recently, transgenic mice expressing the SV40 T antigen under the control of a 2.3 kb promoter fragment of the murine GFAP gene have been described (Danks et al., 1995) . Intragenic regulatory sequences of the GFAP gene were omitted (Sarkar and Cowan, 1991) . Diuse proliferation of subependymal cells occurred, and all founder mice died without transmitting the transgene to their progeny. Although the authors succeeded in establishing cell cultures from two brains of GFAP-T Ag transgenic mice, the histogenesis of these cells is unclear, since they did not express GFAP and their morphology was undierentiated. This outcome is most likely due to large T Ag-mediated transformation of immature neuroectodermal cells, and the observed changes in the CNS resembled the primitive tumors which are commonly induced by T Ag (Eibl et al., 1994) . In the present study we expressed v-src as an initializing event, and we utilized the entire murine GFAP gene for transcriptional regulation. Our mice lived for more than 65 weeks and are therefore capable of accumulating multiple genetic hits ± however, the incidence of manifest tumors was relatively low (520%; wild-type 129sv and C57B1/6 mice observed for the same time span never developed astrocytomas).
The progression from low grade astrocytoma to anaplastic astrocytoma and eventually to glioblastoma is characterized by enhanced cellular proliferation, focal necrosis and pathological neovascularization. Vascular endothelial growth factor (VEGF) and its cellular receptor fetal kinase 1 (Flk-1) are essential for angiogenesis during development (Carmeliet et al., 1996) (Shalaby et al., 1995) , and are among the most potent mediators of tumor angiogenesis (Millauer et al., 1994; Plate et al., 1993 Plate et al., , 1994 . Expression of VEGF is strongly upregulated in glioblastoma, and inhibition of VEGF activity by a dominant-negative¯k-1 mutant resulted in tumor regression in a rat astrocytoma model (Millauer et al., 1994 (Millauer et al., , 1996 . Hypoxic induction of VEGF expression in vitro is triggered by c-src activity, while overexpression of c-src under normoxic conditions did not aect basal VEGF mRNA levels (Mukhopadhyay et al., 1995b) .
In line with the in vitro ®ndings mentioned above, we found colocalisation of v-src and VEGF expression in lesions of GFAP-v-src transgenic mice, which is consistent with the fact that v-Src can upregulate VEGF promoter activity in a dose-dependent manner in human U87 glioblastoma cells (Mukhopadhyay et al., 1995a) . In larger lesions expression of¯k-1 and endothelial proliferation were induced, indicative of emerging neovascularization. Because of size constraints, intracranial tumors in the mouse may not have reached the mass necessary for manifest vascular proliferation, especially when localized in clinically critical sites, e.g. the brain stem. In contrast, the full picture of necrotic areas and vascular proliferation developed in the subcutaneous tumor. We hypothesize that the additional trigger by hypoxia via c-src activation (Mukhopadhyay et al., 1995b) , indicated by enhanced expression of VEGF in pseudopalisading cells surrounding necrotic areas, resulted in the full manifestation of endothelial proliferation.
The multistep nature of tumorigenesis in the mice described above makes them an ideal model to identify co-operating genetic hits, for example using a proviral tagging strategy. It is our hope that the latter will prove important also for initiation and progression of spontaneous human astrocytomas.
Materials and methods
Plasmid construction and generation of transgenic mice
Two NotI sites were linked to a 2.7 kb BamHI fragment encoding the v-src cDNA from the Schmidt-Ruppin strain of RSV. The ®rst NotI site was introduced by ligation of the v -src frag ment with the BamHI linearized pBSSK+vector. The second NotI site was attached by ligation of adapter molecules to pBSSK+/v-src bluntended with EcoRV. After digestion with NotI the v-src fragment was cloned into the unique NotI site of an expression vector derived from the murine glial ®brillary acidic protein (GFAP) gene (Toggas et al., 1994) . The resulting 17 kb GFAP v-src construct was linearized in its prokaryotic portion with S®I and microinjected into fertilized eggs of (C57BL/6JxC3H) F 1 hybrid mice. Eggs were subsequently re-implanted into pseudo-pregnant foster mothers by standard techniques (Hogan et al., 1986) . In all studies, hemizygous transgenic mice were mated to wild-type mice of the same hybrid and the ospring were compared to age-matched wild-type littermates.
Genotyping of transgenic mice
Transgenic ospring were identi®ed by PCR of tail DNA and con®rmed by Southern blot hybridization using a 32 Plabeled S®I-fragment of the construct as a probe. Aliquots of tail DNA (100 ng) were subjected to PCR ampli®cation with a sense primer termed E1-s (5'-TGGAGCGCA-GACGCATCACC-3') located in exon 1 of the GFAP gene, and an antisense primer termed v-src-a (5'-GCAGCACACAGACAAAAGCGT-3') located in the 5' region of the v-src insert in a 20 ml mix containing 16 reaction buer [50 mM KCl, 10 mM Tris-HCl, pH 9.0, 1% Triton X-100, 1.25 mM MgCl 2 ], 5% DMSO, 0.25 mM dNTPs (Pharmacia-Biotech), 10 pmol of each primer, and 1 U of Taq DNA polymerase (Promega). PCR was performed for 30 cycles in a Perkin Elmer Cetus DNA Thermal Cycler TC1 with melting at 948C, annealing at 598C and elongation at 728C for 1 min each. Ampli®ed products were separated and visualized on 2% agarose gels stained with ethidium bromide.
For Southern hybridization analysis, 10 mg tail DNA were digested with BamHI or PvuII (40 U), electrophoresed through 0.8% agarose gel and transferred to Hybond-N + membranes (Amersham, UK) in alkaline buer (1 M NaCl, 0.5 M NaOH). After u.v. cross-linking, membranes were hybridized to a GFAP-v-src-speci®c probe labeled with a-[ 32 P]dATP (3000 Ci/nmol, Amersham). Hybridization was performed at 428C for 16 h in 5.56 sodium chloride citrate (SSC), 13.3% formamide, 0.1 M Tris-HCl (pH 9.0), 0.1% Denhardt's solution, 1% sodium dodecyl sulfate (SDS), 100 mg/ml yeast tRNA (Boehringer, Mannheim) using 10 6 c.p.m./ml of radiolabeled probe. Membranes were washed with 66SSC, 0.1% SDS at room temperature for 5 min and at 558C for 20 min and were visualized by autoradiography and phosphorimaging.
Preparation of tumor cell culture
Cell cultures were prepared from a subcutaneous tumor of a 20 week old src2 mouse. After thorough washing in sterile PBS, tumor tissue was minced and pressed through 100 mm and 70 mm cell strainers (Falcon, Becton Dickinson). Dissociated tumor cells were grown in Dulbecco's modi®ed Eagle's medium (DMEM) (Gibco, BRL) containing 10% fetal bovine serum (Sigma), penicillin, and streptomycin in the presence of 5% CO 2 and 95% air. These cells were harvested for RNA extraction and preparation of cellular lysates containing Src and GFAP antigens.
Analysis of transgene transcription in tissue homogenates and cell extracts
Transcription of the transgene was assessed by Northern blotting and by RT ± PCR on organ extracts. Total RNA was prepared from snap-frozen tissues or cell extracts using the acid-phenol guanidinium method (Chomczynski and Sacchi, 1987) . Poly(A) + RNA was enriched with the PolyATract 1 System (Promega). 10 mg of total RNA or 5 mg of poly(A) + RNA was denatured with glyoxal, fractionated by electrophoresis on a 1% agarose gel, blotted and membranes were hybridized with 32 P-labeled v-src and GAPDH cDNA, respectively, as described previously (Aguzzi et al., 1996) .
In addition, total RNA (1 mg) from tissues was reversetranscribed with recombinant Moloney Murine Leukemia Virus reverse transcriptase (GeneAmp 1 Kit, Perkin Elmer) in a ®nal volume of 20 ml. 25% of the cDNA was PCRampli®ed using primers E1-s and v-src-a, and analysed on a 2% agarose gels. For assessment of endogenous mouse GFAP expression, we used primers E1-s and E3-a (5'-AGGAATTCTTGACCTTAGAGG-3'). For murine b-actin expression analysis, we used primers as described (Sands et al., 1994) .
Histology and immunohistochemistry
Transgenic mice aged between 2 and 65 weeks were analysed. All animals were injected with 20 mg/kg of 5-Bromo-2'-deoxyuridine (BrdU) 24 h and 4 h before sacri®ce. Organs were removed, ®xed overnight in 4% (wt/vol) paraformaldehyde in PBS, and embedded in paran. Bone and spinal cord were ®xed as above, followed by decalci®cation in 0.5 M EDTA, pH 8.0 for 10 d. 2 mm coronal and parasagittal sections were mounted on silanized slides and stained with hematoxylin and eosin (H&E). Immunohistochemistry was performed using polyclonal antibodies to glial ®brillary acidic protein (GFAP, DAKO, 1 : 300), synaptophysin (DAKO, 1 : 40), and microtubule associated protein-2 (MAP-2, Boehringer Mannheim, 1 : 1000). BrdU incorporation was detected with a monoclonal anti-BrdU-antibody (Caltag Laboratories). Biotinylated secondary antibodies (DAKO, 1 : 200), biotin/avidin-peroxidase (DAKO) and diaminobenzidine (Sigma) as chromogen were employed according to the instructions of the vendors.
Detection of transgenic protein by immunoblotting
Proteins from whole cell lysates or tissue homogenates were extracted in buer containing 50 mM Tris-HCl, pH 7.4; 1% NP-40; 0.25% sodium deoxycholate; 150 mM NaCl; 1 mM EGTA; 1 mM PMSF; 1 mg/ml aprotinin, leupeptin, pepstatin; 1 mM Na 3 VO 4 ; 1 mM NaF, separated on 10% SDS-polyacrylamide gels (Laemmli, 1970) and transferred to nitrocellulose (Schleicher and Schuell). Membranes were incubated with either rabbit antiserum to GFAP (DAKO) or monoclonal mouse antibodies to pp60 src (Oncogene Science). Primary antibodies were detected by horseradish peroxidase-conjugated secondary antibody (DAKO) and chemiluminescence reagents (ECL TM Amersham Life Science).
In situ hybridization
Sense and antisense RNA probes were transcribed in vitro with T3 and T7 RNA polymerase from linearized pBlusescript vectors carrying cDNAs for v-src, GFAP (Lewis et al., 1984) , synaptophysin (Leube et al., 1989) , proteolipid protein (Milner et al., 1985) , VEGF (Breier et al., 1992) ,¯k-1 and¯t-1 (Breier et al., 1995) in the presence of digoxigenin-11-dUTP (Boehringer Mannheim). 50 ± 200 ng of labeled transcripts (0.7 ± 1.2 kb) were hybridized to tissue sections at 658C as described (Marino et al., 1995) . Digoxigenin was detected with alkaline phosphatase-labeled anti-digoxigenin Fab fragments and 4-nitro blue tetrazolium/5-bromo-4-chloro-3-indolyl phosphate (Boehringer Mannheim). Coverslips were mounted with glycerol gelatine. For double staining, slides were hybridized with probes for v-src and GFAP, and subsequently processed for BrdU immunohistochemistry.
